Divi's Lab Peer Comparison

NSE: DIVISLAB | BSE: 532488

₹9,780.00

₹116.00 (1.20%)

As on 30-Oct-2026IST

Market cap

₹2,57,903 Cr

Revenue (TTM)

₹11,230 Cr

P/E Ratio

88.2

P/B Ratio

14.6

Div. Yield

0.3 %

Edit

	Divi's Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	2,57,903	35,440	25,276	17,311	13,028
Revenue (₹ Cr)	11,230	9,683	2,372	2,684	1,170
Net Profit (₹ Cr)	2,925.00	1,018.97	497.77	669.74	279.64
Net Margin (%)	25.04	10.47	20.72	24.24	22.94
RoE (%)	18.53	21.30	28.49	19.79	13.92
Price to Earnings	88.17	35.04	50.78	25.85	46.13
Price-To-Book	14.60	6.78	12.51	4.77	6.28

Income Statement (₹ Cr)

	Divi's Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	11,230.00	9,683.45	2,371.81	2,684.41	1,170.41
Total Income	11,682.00	9,730.84	2,402.61	2,763.43	1,218.73
Total Expenditure	7,263.00	7,739.53	1,608.91	1,761.70	766.14
EBITDA	3,967.00	1,943.92	762.90	922.70	404.27
Depreciation	484.00	425.10	98.11	82.27	74.77
EBIT	3,483.00	1,518.82	664.79	840.44	329.50
Interest	26.00	148.45	26.33	5.42	0.24
Other Income	452.00	47.39	30.80	79.02	48.32
Exceptional Items	-74.00	-27.85	0.00	-25.66	-3.28
Profit before Tax	3,835.00	1,389.91	669.26	888.39	374.31
Provision for Tax	910.00	370.94	171.48	218.65	94.68
Profit after Tax	2,925.00	1,018.97	497.77	669.74	279.64

	Divi's Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	16,761.00	4,950.03	1,874.47	3,631.29	2,075.76
Minority Interest	0.00	-7.58	0.00	0.00	3.07
Non-Current Liabilities	1,229.00	723.57	345.47	146.95	53.38
Current Liabilities	2,043.00	3,912.24	710.20	563.70	201.71
Total Liabilities	20,878.00	9,514.48	2,930.14	4,157.10	2,231.79

	Divi's Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	8,717.00	3,392.16	1,290.62	1,454.42	980.16
Current Assets	11,096.00	5,612.10	1,483.13	2,864.85	1,290.68
Total Assets	20,878.00	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	0.00	1,204.08	196.61	0.00	0.00
Net Current Assets	9,053.00	1,699.86	772.93	2,301.15	1,088.97
Contingent Liabilities	8.00	258.92	13.18	4.82	3.76

	Divi's Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	2,738.00	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-2,219.00	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	-804.00	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	-285.00	93.92	-56.08	-69.08	11.28

	Divi's Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	21.51	25.25	27.50	24.61	18.04
ROE (%)	18.53	21.30	28.49	19.79	13.92
ROA (%)	15.83	11.42	19.48	16.78	12.86
EBIT Margin (%)	31.02	15.68	28.03	31.31	28.15
Net Margin (%)	25.04	10.47	20.72	24.24	22.94
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Divi's Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	16.35	18.36	78.33	8.19	4.02
EBIT Growth (%)	31.09	30.43	303.07	24.77	-11.95
Net Profit Growth (%)	26.84	32.39	182.61	26.27	-12.44
EPS Growth (%)	29.24	36.68	277.72	29.79	-12.06
Book Value Growth (%)	11.97	11.36	22.95	18.43	11.27

	Divi's Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	86.54	34.32	50.78	25.07	45.73
Price / Book Value	14.60	6.78	12.51	4.97	6.28
Dividend Yield (%)	0.31	0.19	0.17	0.36	0.61
EV/EBITDA	64.15	18.77	32.92	17.91	31.20
Market Cap (₹ Cr)	1,57,583.71	30,257.56	15,412.11	11,956.86	10,627.92

	Divi's Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.00	0.05	0.09	0.00	0.00
Short term debt to equity ratio	--	0.16	--	--	--
Current Ratio	5.43	1.43	2.09	5.08	6.40
Quick Ratio	3.50	0.82	1.37	3.69	4.43
Interest Coverage	148.50	10.36	26.41	165.03	1,593.82

	Divi's Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	26.57	26.46	22.82	36.81	35.24
Asset Turnover	0.61	1.09	0.93	0.67	0.54
Receivable days	99.21	88.68	77.32	144.58	169.86
Inventory Days	124.81	84.11	80.83	96.67	97.92
Payable days	94.57	176.65	125.94	135.45	159.68
Cash Conversion Cycle	129.45	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.